MannKind Corporation (MNKD), Eli Lilly & Co. (LLY): The Easiest Prediction in Biotech This Summer

MannKind Corporation (NASDAQ:MNKD) is scheduled to release data for two phase 3 trials of its inhaled insulin, Afrezza, this month.

Nothing is for certain in biotech, but it looks to me like the extended phase 3 program has an extremely high likelihood of coming up positive. I’ll be shocked if both trials don’t meet their endpoints.

Why the clinical trials will be positive
Simply put, there isn’t that much difference between the product MannKind Corporation (NASDAQ:MNKD) studied in its previous successful phase 3 trials and the device used in its current trials, Affinity 1 and Affinity 2.

The new inhaler, dubbed Dream Boat, is smaller than MedTone, but there’s little reason to think the underlying insulin will do anything differently once it enters the body.


Source: MannKind.

In previous clinical trials, dubbed Study 102, Afrezza was able to lower A1C levels, a long-term measure of blood sugar levels, by about the same amount as injected insulin. Afrezza, which dropped A1C by 0.59 points, technically didn’t perform quite as well as injected insulin, which dropped A1C by 0.71 points, but the difference wasn’t great enough to say injected insulin was better.

MannKind Corporation (NASDAQ:MNKD)MannKind Corporation (NASDAQ:MNKD) thinks part of the reason why its A1C levels don’t look quite as good stems from the way the two products change blood sugar levels. Rapid-acting injected insulins, such as Novo Nordisk A/S (ADR) (NYSE:NVO)‘s NovoLog and Eli Lilly & Co. (NYSE:LLY)‘s Humalog, tend to produce lower fasting blood sugar levels compared to Afrezza. Hypoglycemia — low blood sugar levels — is extremely dangerous, so the long-acting insulin that diabetics also use is adjusted so the patient’s blood sugar level is high enough that the lows between meals don’t become too low.

Since the fasting lows aren’t nearly as low for patients taking Afrezza, patients can start with lower blood sugar levels. To produce parity, patients in the Affinity 1 trial are required to reduce their blood sugar level to a certain level before Afrezza or the rapid-acting insulin is tested.

If Afrezza can lower A1C levels more than injected insulins and/or produce fewer hypoglycemia events, it will make it much easier for MannKind Corporation (NASDAQ:MNKD) to take market share from NovoLog and Humalog.

The second trial, Affinity 2, compares Afrezza to placebo in type 2 diabetics who haven’t gone on insulin yet. We have less data on MannKind in this patient population, but the drug is being compared to placebo, so it shouldn’t be that hard to show insulin is capable of lowering blood glucose levels (that’s what it does naturally in those of us who don’t have diabetes).

All priced in
Despite the high likelihood of success, it’s hard to recommend buying MannKind Corporation (NASDAQ:MNKD) after the monster run it’s had this year.

MNKD Chart
MNKD data by YCharts.

Getting positive clinical trial data is only the first step. For MannKind Corporation (NASDAQ:MNKD) to justify its $2 billion market cap, the biotech needs to get the drug approved, find a partner, and build a market for Afrezza. Those risks are covered further in a companion article this weekend.

The article The Easiest Prediction in Biotech This Summer originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

The 10 Largest Armies in the World: Who Should We Be Afraid Of?

Best Warren Buffett Quotes on Money You Need to Hear

The 10 Highest Suicide Rates by Profession

The 20 Most Underrated Movies of All Time

The 10 Fastest Growing Companies in America

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!